[Spontaneous hemopneumothorax]

Same author

Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same author

Corrigendum to "Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial": [Ann Oncol 36 (2025) 775-785].

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same author

Global advances and future directions in lung cancer care: expert consensus and strategic priorities.

ESMO open·2026

Same author

Genomic actionability and matched targeted therapy in a decade-long institutional precision medicine program for solid tumors.

ESMO open·2025

Same author

Frequent high-level rifaximin resistance in <i>Escherichia coli</i> associated with long-term treatment of patients with liver cirrhosis: a prospective, controlled study.

Microbiology spectrum·2025

Same author

Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial.

ESMO open·2025

Same journal

Vaccination status of patients undergoing HIV treatment in a hospital in Madrid.

Revista clinica espanola·2026

Same journal

Sulfonylureas and fracture risk in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.

Revista clinica espanola·2026

Same journal

Risk factors for the development of in-hospital complications in pluripathological patients.

Revista clinica espanola·2026

Same journal

Features, treatment and 1-year prognosis of patients with heart failure and chronic kidney disease stages 4 or 5.

Revista clinica espanola·2026

Same journal

Notification of suspected adverse drug reactions by nurses to a hospital pharmacovigilance program. Retrospective descriptive study.

Revista clinica espanola·2026

Same journal

Venous thromboembolic disease associated with hormonal contraceptives. Venous Thromboembolism Group of the Spanish Society of Internal Medicine and the Catalan Society of Contraception.

Revista clinica espanola·2026

Related Experiment Videos

[Spontaneous hemopneumothorax]

Related Concept Videos

Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study.

Corrigendum to "Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial": [Ann Oncol 36 (2025) 775-785].

Global advances and future directions in lung cancer care: expert consensus and strategic priorities.

Genomic actionability and matched targeted therapy in a decade-long institutional precision medicine program for solid tumors.

Frequent high-level rifaximin resistance in <i>Escherichia coli</i> associated with long-term treatment of patients with liver cirrhosis: a prospective, controlled study.

Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial.

Vaccination status of patients undergoing HIV treatment in a hospital in Madrid.

Sulfonylureas and fracture risk in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.

Risk factors for the development of in-hospital complications in pluripathological patients.

Features, treatment and 1-year prognosis of patients with heart failure and chronic kidney disease stages 4 or 5.

Notification of suspected adverse drug reactions by nurses to a hospital pharmacovigilance program. Retrospective descriptive study.

Venous thromboembolic disease associated with hormonal contraceptives. Venous Thromboembolism Group of the Spanish Society of Internal Medicine and the Catalan Society of Contraception.

Related Experiment Videos

[Spontaneous hemopneumothorax]

Related Concept Videos

Related Articles

Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study.

Corrigendum to "Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial": [Ann Oncol 36 (2025) 775-785].

Global advances and future directions in lung cancer care: expert consensus and strategic priorities.

Genomic actionability and matched targeted therapy in a decade-long institutional precision medicine program for solid tumors.

Frequent high-level rifaximin resistance in <i>Escherichia coli</i> associated with long-term treatment of patients with liver cirrhosis: a prospective, controlled study.

Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial.

Vaccination status of patients undergoing HIV treatment in a hospital in Madrid.

Sulfonylureas and fracture risk in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.

Risk factors for the development of in-hospital complications in pluripathological patients.

Features, treatment and 1-year prognosis of patients with heart failure and chronic kidney disease stages 4 or 5.

Notification of suspected adverse drug reactions by nurses to a hospital pharmacovigilance program. Retrospective descriptive study.

Venous thromboembolic disease associated with hormonal contraceptives. Venous Thromboembolism Group of the Spanish Society of Internal Medicine and the Catalan Society of Contraception.